Holocene Advisors
SLNO

Holocene Advisors’s Soleno Therapeutics SLNO Stock Holding History

Holocene Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-997,069
Closed -$67.4M – 880
2025
Q3 		$67.4M Sell
997,069
-155,979
-14% -$11.6M 0.15% 149
2025
Q2 		$96.6M Sell
1,153,048
-43,942
-4% -$3.29M 0.24% 116
2025
Q1 		$85.5M Buy
1,196,990
+241,523
+25% +$11.8M 0.25% 120
2024
Q4 		$42.9M Buy
955,467
+361,103
+61% +$18.7M 0.14% 178
2024
Q3 		$30M Buy
594,364
+57,913
+11% +$2.77M 0.12% 185
2024
Q2 		$21.9M Buy
+536,451
New +$22.7M 0.09% 208

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Holocene Advisors's SLNO Position: Q4 2025 in Review

Holocene Advisors sold out of Soleno Therapeutics (SLNO) in Q4 2025, closing a stake of 997,069 shares — an estimated $67.4M sold.

Holocene Advisors first reported a position in SLNO in Q2 2024 and held it in 6 quarters. The position peaked at $96.6M in Q2 2025. 248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

  • Holocene Advisors reported no remaining Soleno Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Holocene Advisors sold 997,069 Soleno Therapeutics shares in Q4 2025, an estimated $67.4M.
  • Holocene Advisors first reported a position in Soleno Therapeutics in Q2 2024 and held it in 6 quarters.
  • Holocene Advisors's Soleno Therapeutics position peaked at $96.6M in Q2 2025.
  • 248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on Holocene Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.